Agilent Technologies (A)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$171.78-3.04%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
QuarterlyIQ Insights · A
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 14.8% |
| Our one-year growth estimate | diamond | 7.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 7.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 13 industry peers
A — CFO transition
Dated 2026-09-08
Director — Boon Hwee Koh: The Chairperson retired after 23 years of service and was immediately succeeded by a qualified independent director, representing an orderly board succession rather than a disruptive executive loss.
Why it matters: Q3 margin gained help from tariff refunds. Q4 guidance includes no future refund benefit, so results can test underlying cost gains.
Watch forQ4 non-GAAP EPS is at least $1.71, and FY26 margin expansion is above 130 basis points.
Also watch forQ4 non-GAAP EPS is below $1.71, or FY26 margin expansion is 130 basis points or less.
Why it matters: The report is the next scheduled test of Agilent's higher FY26 targets. It can show whether Q4 sales and EPS meet the latest ranges.
Watch forThe Nov. 23 report shows Q4 revenue of at least $1.98 billion and non-GAAP EPS of at least $1.71.
Also watch forThe Nov. 23 report shows Q4 revenue below $1.98 billion or non-GAAP EPS below $1.71.
Why it matters: Agilent raised its FY26 EPS range after Q3. Meeting the new low end would support its earnings growth plan.
Supportive ifFY26 non-GAAP EPS is at least $6.18.
Worry ifFY26 non-GAAP EPS is below $6.18 or management lowers its $6.18 to $6.21 range.
Why it matters: LDG was Agilent's fastest-growing group in Q3. Continued growth would support its stated plan to grow this business.
Supportive ifLDG year-over-year core revenue growth is at least 9% in the next reported quarter.
Worry ifLDG year-over-year core revenue growth falls below 9%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$103 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $298 loss on $10,000 · 3.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,975 loss on $10,000 · 29.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Agilent guided to 5.2% to 6.2% core growth for Q4. A result above the low end would back its stronger growth outlook.
Supportive ifQ4 core revenue growth is at least 5.2%, and reported revenue is at least $1.98 billion.
Worry ifQ4 core revenue growth is below 5.2% or reported revenue is below $1.98 billion.